Metastatic melanoma: The new era of targeted therapy

Michele Guida, Salvatore Pisconte, Giuseppe Colucci

Research output: Contribution to journalArticle

Abstract

Introduction: Metastatic melanoma is one of the most resistant tumors to standard chemotherapy, with a median overall survival of 6 - 8 months. Previously approved drugs offer only marginal survival advantages. Advances in the understanding of melanoma biology and host immunity have recently opened the field to new therapeutic approaches. Thus, after many years of disappointing results, a new era in the treatment of melanoma is beginning. Areas covered: This review discusses new advances in the treatment of metastatic melanoma. Current data regarding the new agents under clinical development are reviewed, including emerging data from recently completed clinical trials, as well as preliminary data from ongoing studies testing novel therapeutic strategies. Expert opinion: The new agents specifically targeted against melanoma are changing the standard of care for this disease. The monoclonal antibody ipilimumab is the first new agent approved for first- and second-line treatment of metastatic melanoma, based on improved overall survival compared -with standard therapy. Other drugs, such as BRAF inhibitors, have demonstrated high activity in the advanced disease and will be reaching clinical approval. Researchers are already planning ways to combine some of these new drugs in order to render possible a longer control of tumor.

Original languageEnglish
JournalExpert Opinion on Therapeutic Targets
Volume16
Issue numberSUPPL.2
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Melanoma
Tumors
Pharmaceutical Preparations
Chemotherapy
Therapeutics
Monoclonal Antibodies
Planning
Expert Testimony
Testing
Standard of Care
Immunity
Neoplasms
Research Personnel
Clinical Trials
Drug Therapy
ipilimumab

Keywords

  • metastatic melanoma
  • new drugs
  • targeted therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Metastatic melanoma : The new era of targeted therapy. / Guida, Michele; Pisconte, Salvatore; Colucci, Giuseppe.

In: Expert Opinion on Therapeutic Targets, Vol. 16, No. SUPPL.2, 04.2012.

Research output: Contribution to journalArticle

Guida, Michele ; Pisconte, Salvatore ; Colucci, Giuseppe. / Metastatic melanoma : The new era of targeted therapy. In: Expert Opinion on Therapeutic Targets. 2012 ; Vol. 16, No. SUPPL.2.
@article{a920e7cd671b468a8e32ffd481aa6889,
title = "Metastatic melanoma: The new era of targeted therapy",
abstract = "Introduction: Metastatic melanoma is one of the most resistant tumors to standard chemotherapy, with a median overall survival of 6 - 8 months. Previously approved drugs offer only marginal survival advantages. Advances in the understanding of melanoma biology and host immunity have recently opened the field to new therapeutic approaches. Thus, after many years of disappointing results, a new era in the treatment of melanoma is beginning. Areas covered: This review discusses new advances in the treatment of metastatic melanoma. Current data regarding the new agents under clinical development are reviewed, including emerging data from recently completed clinical trials, as well as preliminary data from ongoing studies testing novel therapeutic strategies. Expert opinion: The new agents specifically targeted against melanoma are changing the standard of care for this disease. The monoclonal antibody ipilimumab is the first new agent approved for first- and second-line treatment of metastatic melanoma, based on improved overall survival compared -with standard therapy. Other drugs, such as BRAF inhibitors, have demonstrated high activity in the advanced disease and will be reaching clinical approval. Researchers are already planning ways to combine some of these new drugs in order to render possible a longer control of tumor.",
keywords = "metastatic melanoma, new drugs, targeted therapy",
author = "Michele Guida and Salvatore Pisconte and Giuseppe Colucci",
year = "2012",
month = "4",
doi = "10.1517/14728222.2011.645807",
language = "English",
volume = "16",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "SUPPL.2",

}

TY - JOUR

T1 - Metastatic melanoma

T2 - The new era of targeted therapy

AU - Guida, Michele

AU - Pisconte, Salvatore

AU - Colucci, Giuseppe

PY - 2012/4

Y1 - 2012/4

N2 - Introduction: Metastatic melanoma is one of the most resistant tumors to standard chemotherapy, with a median overall survival of 6 - 8 months. Previously approved drugs offer only marginal survival advantages. Advances in the understanding of melanoma biology and host immunity have recently opened the field to new therapeutic approaches. Thus, after many years of disappointing results, a new era in the treatment of melanoma is beginning. Areas covered: This review discusses new advances in the treatment of metastatic melanoma. Current data regarding the new agents under clinical development are reviewed, including emerging data from recently completed clinical trials, as well as preliminary data from ongoing studies testing novel therapeutic strategies. Expert opinion: The new agents specifically targeted against melanoma are changing the standard of care for this disease. The monoclonal antibody ipilimumab is the first new agent approved for first- and second-line treatment of metastatic melanoma, based on improved overall survival compared -with standard therapy. Other drugs, such as BRAF inhibitors, have demonstrated high activity in the advanced disease and will be reaching clinical approval. Researchers are already planning ways to combine some of these new drugs in order to render possible a longer control of tumor.

AB - Introduction: Metastatic melanoma is one of the most resistant tumors to standard chemotherapy, with a median overall survival of 6 - 8 months. Previously approved drugs offer only marginal survival advantages. Advances in the understanding of melanoma biology and host immunity have recently opened the field to new therapeutic approaches. Thus, after many years of disappointing results, a new era in the treatment of melanoma is beginning. Areas covered: This review discusses new advances in the treatment of metastatic melanoma. Current data regarding the new agents under clinical development are reviewed, including emerging data from recently completed clinical trials, as well as preliminary data from ongoing studies testing novel therapeutic strategies. Expert opinion: The new agents specifically targeted against melanoma are changing the standard of care for this disease. The monoclonal antibody ipilimumab is the first new agent approved for first- and second-line treatment of metastatic melanoma, based on improved overall survival compared -with standard therapy. Other drugs, such as BRAF inhibitors, have demonstrated high activity in the advanced disease and will be reaching clinical approval. Researchers are already planning ways to combine some of these new drugs in order to render possible a longer control of tumor.

KW - metastatic melanoma

KW - new drugs

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84858988078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858988078&partnerID=8YFLogxK

U2 - 10.1517/14728222.2011.645807

DO - 10.1517/14728222.2011.645807

M3 - Article

C2 - 22443134

AN - SCOPUS:84858988078

VL - 16

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - SUPPL.2

ER -